StockMarketWire.com - Allergy Therapeutics said Monday it had published positive data demonstrating that its grass pollen allergy therapy showed significant and long-lasting symptom improvements in patients 3-6 years after receiving the treatment.

Each of the clinical symptoms – runny nose, sneezing and conjunctivitis – were statistically significantly reduced in treated patients compared with controls without allergen-specific immunotherapy, Allergy said.

'We are delighted with the publication of our observational study that demonstrates the long-term effects of Pollinex Quattro Grass immunotherapy,' said Professor Stefan Zielen, author of the paper.

'Our paper highlights the benefits that this allergen-specific immunotherapy can offer allergy sufferers, in terms of patient convenience, as well as the potential for positive and long-lasting effects.'


At 9:51am: [LON:AGY] Allergy Therapeutics PLC share price was +0.75p at 28.25p



Story provided by StockMarketWire.com